Claims for Patent: RE47929

Summary for Patent: RE47929

Title:	Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
Abstract:	Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
Inventor(s):	Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Shuqun Lin, Steven H. Spergel, Yanlei Zhang
Assignee:	Bristol Myers Squibb Co
Application Number:	US16/201,653
Patent Claims:	1. A compound which is or a stereoisomer or pharmaceutically-acceptable salt thereof. 2. A compound according to claim 1 which is or a stereoisomer or pharmaceutically-acceptable salt thereof. 3. A compound according to claim 2 which is or a stereoisomer or pharmaceutically-acceptable salt thereof. 4. A compound according to claim 2 which is or a stereoisomer or pharmaceutically-acceptable salt thereof. 5. A compound according to claim 2 which is or a stereoisomer or pharmaceutically-acceptable salt thereof. 6. A compound according to claim 3 which is or a stereoisomer or pharmaceutically-acceptable salt thereof. 7. A pharmaceutical composition comprising one or more compounds according to claim 1 and a pharmaceutically acceptable carrier or diluent. 8. A pharmaceutical composition comprising a compound according to claim 6 and a pharmaceutically acceptable carrier or diluent. 9. A method of treating a disease, comprising administering to a patient in need of such treatment a therapeutically-effective amount of a compound according to claim 6 wherein the disease is systemic lupus erythematosus. 10. A compound having the structure 11. A pharmaceutically acceptable salt of a compound having the structure 12. The pharmaceutically acceptable salt according to claim 11, which is a monohydrochloride salt. 13. A pharmaceutical composition comprising the compound according to claim 10 and a pharmaceutically acceptable carrier or diluent. 14. A pharmaceutical composition comprising the pharmaceutically acceptable salt according to claim 11 and a pharmaceutically acceptable carrier or diluent. 15. A pharmaceutical composition comprising the pharmaceutically acceptable salt according to claim 12 and a pharmaceutically acceptable carrier or diluent. 16. A method of treating systemic lupus erythematosus in a patient, comprising administering to the patient the compound according to claim 10. 17. A method of treating systemic lupus erythematosus in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 11. 18. A method of treating systemic lupus erythematosus in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 12. 19. A method of treating psoriasis in a patient, comprising administering to the patient the compound according to claim 10. 20. A method of treating psoriasis in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 11. 21. A method of treating psoriasis in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 12. 22. A method of treating psoriatic arthritis in a patient, comprising administering to the patient the compound according to claim 10. 23. A method of treating psoriatic arthritis in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 11. 24. A method of treating psoriatic arthritis in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 12. 25. A method of treating lupus nephritis in a patient, comprising administering to the patient the compound according to claim 10. 26. A method of treating lupus nephritis in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 11. 27. A method of treating lupus nephritis in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 12. 28. A method of treating Sjögren's syndrome in a patient, comprising administering to the patient the compound according to claim 10. 29. A method of treating Sjögren's syndrome in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 11. 30. A method of treating Sjögren's syndrome in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 12. 31. A method of treating inflammatory bowel disease in a patient, comprising administering to the patient the compound according to claim 10. 32. A method of treating inflammatory bowel disease in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 11. 33. A method of treating inflammatory bowel disease in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 12. 34. A method of treating Crohn's disease in a patient, comprising administering to the patient the compound according to claim 10. 35. A method of treating Crohn's disease in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 11. 36. A method of treating Crohn's disease in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 12. 37. A method of treating ankylosing spondylitis in a patient, comprising administering to the patient the compound according to claim 10. 38. A method of treating ankylosing spondylitis in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 11. 39. A method of treating ankylosing spondylitis in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 12.